Resources » Delivering comprehensive care: practical considerations | October 21 2021 – Arabic
LINKS
DETAILS

Year: 2021

Language: Arabic

This resource is also available in: الإنجليزية الفرنسية الأسبانية

Author(s): World Federation of Hemophilia

Format: Video

Delivering comprehensive care: practical considerations | October 21 2021 – Arabic

ADDITIONAL INFORMATION

Listen to this 90-minute webinar, Delivering comprehensive care: practical considerations, presented on October 21, 2021. This is the second of three webinars in the PACT Comprehensive Care Series, designed to support healthcare providers in setting up and strengthening comprehensive care in their centres.

The session was moderated by Dr. Miguel Escobar (WFH Board of Directors). Speakers included Dr. Johnny Mahlangu (Professor in Haematology and Head of School of Pathology in the Faculty of Health Sciences of the University of the Witwatersrand and the National Health Laboratory Service, South Africa), Dr. Sukesh Nair (Professor of laboratory haematology at the Christian Medical College, India), and Dr. Daniela Neme (Hematologist and Medical Director of Foundation of Hemophilia, Argentina).

This session presented information about delivery of comprehensive care, setting up and improving diagnostic services, and outreach and patient identification; followed by a live Q&A period.

This WFH webinar was originally presented in English.

View the first webinar in the series:  Setting up comprehensive care: key principles, services, and roles – in Arabic here.

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

RELATED RESOURCES